

Setting the Stage

Overview of the dapivirine vaginal ring

Sharon Hillier, Ph.D.
University of Pittsburgh


**Meeting the HIV Prevention Needs of Adolescent Girls
and Young Women**

Kisumu, Kenya – 9 February 2018



Vaginal Rings for HIV Prevention

- **Long-acting: monthly or longer**
 - Could support improved adherence
 - Thus better effectiveness
- **Easy to use, comfortable**
 - Flexible ring, can be self-inserted
 - Rarely felt by women or male partners
 - High willingness-to-use
 - Little or no impact on sexual experience
- **Suitable for developing countries**
 - Relatively low manufacturing cost
 - Good safety and acceptability data
- **Potential for drug combinations**



*Important
potential new
option for
women*

What is the dapivirine ring?



- Developed by the International Partnership for Microbicides (IPM) - a nonprofit group
- Intended to be used for a month at a time
 - Women can insert and remove the ring themselves
 - Discreet
- Slowly releases ARV drug dapivirine inside the vagina
- If approved, would be the first HIV prevention method developed specifically for women – and be the first long-acting method


What do we know about the dapivirine ring?

Several studies have been conducted of the ring, including two large Phase III trials – ASPIRE and The Ring Study

ASPIRE

- Conducted by the Microbicide Trials Network (MTN)
- Enrolled **2,629 women age 18-45** at 15 sites in **Malawi, Uganda, South Africa and Zimbabwe**

4,588 women in four countries



- Conducted by the International Partnership for Microbicides (IPM)
- Enrolled **1,959 women age 18-45** at 7 sites in **South Africa and Uganda**

What do we know about the dapivirine ring?

- The ring is very safe
- The ring helps protect against HIV
 - 30% fewer women acquired HIV in the dapivirine ring group than in the placebo group
 - These results include all women – including those who didn't use the ring regularly
- The ring is more effective when it's used
 - Among women older than 21 – who also used the ring more regularly – HIV risk was reduced by 56%
 - Among 18-21 year-olds – no protection (and lowest adherence)
 - Additional analysis – as high as 75% protection with most consistent use across all ages.



Getting used to the ring

- Those who've never used a ring have notions that it will be difficult to use.
- ASPIRE participants said they were unsure about it at first ...
- But got more confident in using it over time.

When I first saw it, it was like, WOW!

It was easy to use ring and it was comfortable, I couldn't feel the ring. Even during my periods, it was no problem at all. During sex, I didn't have doubts about it.


What do we know about the ring in adolescent girls?

- One study has been conducted in the United States among 96 girls ages 15-17
- Participants were asked to use a ring for a month at a time for 6 months
- The dapivirine ring was safe and acceptable, and adherence was very high




What's happening now?

- IPM is seeking regulatory approval for use by women **ages 18-45**, based on results of The Ring Study and ASPIRE, and several smaller studies.
 - The earliest approval is 2019
- In the meantime, we are learning more about how women use the ring in “open-label” studies
 - HOPE for former ASPIRE participants
 - DREAM for former Ring Study participants
- We want to learn more about the ring in high-risk populations
 - Adolescent girls and young women – REACH
 - Pregnant and breastfeeding women



Regulatory Path: Overview



Regulatory Timeline


2016

2017

2018

2019

2020



Results

Open-label extension study: DREAM



Open-label extension study: HOPE



African adolescents safety study: REACH



Supporting safety and
PK studies

Safety studies in pregnant and
breastfeeding women

EMA Article 58

WHO PQ


African NRAs
(submission & approval)

US FDA

S. Afr. MCC (SAHPRA)

When will the ring be available?

Learning from History: Oral PrEP



Approval pathway for new HIV prevention drug can be more complex than for a drug already approved for treatment (e.g., oral Truvada for PrEP)





Discussion
